156 related articles for article (PubMed ID: 23916787)
41. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
42. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
43. [The reflection of the dynamics of the serum markers CA l5.3 and CEA in breast cancer].
Cianga C; Suliman I
Rev Med Chir Soc Med Nat Iasi; 1998; 102(3-4):93-5. PubMed ID: 10756852
[TBL] [Abstract][Full Text] [Related]
44. [Neoadjuvant therapy of breast cancer using Newcastle disease virus].
Keshelava VV; Dobrovol'skaia NIu; Chazova NL; Bershchanskaia AM; Podol'skaia MV; Garmarnik TV; Mel'nikova NV
Vopr Onkol; 2009; 55(4):433-5. PubMed ID: 19947365
[TBL] [Abstract][Full Text] [Related]
45. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
46. Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer.
Wan F; Dong L; Zhang F; Wang Y; Chen F; Ni S; Chen Y; Long J
J Int Med Res; 2013 Jun; 41(3):743-53. PubMed ID: 23696593
[TBL] [Abstract][Full Text] [Related]
47. Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Lehner J; Stötzer OJ; Fersching DM; Nagel D; Holdenrieder S
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):59-62. PubMed ID: 23260002
[No Abstract] [Full Text] [Related]
48. [Plasma DNA measurement as a biomarker of cancer].
Czeiger D; Agassi R; Sebbag G; Zlotnik A; Douvdevani A; Shaked G
Harefuah; 2014 Oct; 153(10):569-72, 625. PubMed ID: 25518072
[TBL] [Abstract][Full Text] [Related]
49. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
[TBL] [Abstract][Full Text] [Related]
50. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A
Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176
[TBL] [Abstract][Full Text] [Related]
51. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
[TBL] [Abstract][Full Text] [Related]
52. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.
Kamel AM; Teama S; Fawzy A; El Deftar M
Tumour Biol; 2016 Jun; 37(6):7565-72. PubMed ID: 26684805
[TBL] [Abstract][Full Text] [Related]
53. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.
Duffy MJ; McDermott EW; Crown J
Tumour Biol; 2018 May; 40(5):1010428318776169. PubMed ID: 29775157
[TBL] [Abstract][Full Text] [Related]
54. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
55. EXPRESSION OF ALU REPEAT IN BLOOD PLASMA OF PATIENTS WITH BREAST CANCER DURING NEOADJUVANT CHEMOTHERAPY: AN EXPLORATORY STUDY.
Özgür E; Ferhatoglu F; Sen F; Saip P; Gezer U
Exp Oncol; 2023 Jun; 45(1):120-124. PubMed ID: 37417275
[TBL] [Abstract][Full Text] [Related]
56. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
57. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
58. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
[TBL] [Abstract][Full Text] [Related]
59. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
60. Electrochemical immunosensors in breast and ovarian cancer.
Diaconu I; Cristea C; Hârceagă V; Marrazza G; Berindan-Neagoe I; Săndulescu R
Clin Chim Acta; 2013 Oct; 425():128-38. PubMed ID: 23933123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
